Genomic and Proteomic Markers of Cervical Cancer: a Prospective Outlook

Gynaecological malignancy is a major challenge in women’s health worldwide. Cervical cancer (CC) is a particularly common type affecting the female reproductive system through an uncontrolled cell propagation causing cervical tissue injury in women. The advent of new technologies empowers research into the discovery and development of novel markers for early diagnosis, as well as therapy evaluation and monitoring. Despite manifold attempts to unravel the molecular mechanisms of CC, its pathogenesis remains largely unclear. The study of putative CC predictors is key to the invention of effective alleviating treatments. Systems biology enabled with high-throughput methods currently provides routes to tackle this problem. Unlike a traditional approach, it generates a wealth of data on prognostic biomarkers and therapeutic targets in cervical cancer, fuelling the search for novel high-sensitive and specific molecular markers. This approach will help improve the early diagnosis and treatment efficacy at a lower relapse rate. This review presents the currently on-stage and emerging biomarkers in cellular and molecular research into cervical cancer detection and prognosis.

1. Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer new concepts and clinical implications. Cancer Medicine 2018;7(10):5217–36. DOI: 10.1002/cam4.1501

2. Christensen J.T., Grønhøj C., Zamani M., Brask J., Kjær E., Lajer H., et al. Association between oropharyngeal cancers with known HPV and p16 status and cervical intraepithelial neoplasia: a Danish population-based study. Acta Oncologica. 2018;58(3):267–72. DOI: 10.1080/0284186X.2018.1546059

3. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (editors). State of cancer care for population in Russia in 2019. Moscow: National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2020 (In Russ.).

4. Global strategy to accelerate the elimination of cervical cancer as a public health problem. WHO; 2020. 52 p.

5. Dmitriadi T.A., Kit O.I., Burtsev D.V. Screening of cervical cancer. World experience. Situation in Russia. Bulletin of higher education institutes. North Caucasus region. Natural sciences. 2017;4-2(196-2):26–32 (In Russ). DOI: 10.23683/0321-3005-2017-4-2-26-32

6. Valenti G., Vitale S.G., Tropea A., Biondi A., Laganà A.S. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates Surg. 2017;69:441–9. DOI: 10.1007/s13304-017-0491-3

7. Lees B., Erickson B.K., Huh W.K. Cervical cancer screening: evidence behind the guidelines. Obstet Gynecol. 2016;214(4):438–43. DOI: 10.1016/j.ajog.2015.10.147

8. Shah U.J., Nasiruddin M., Dar S.A., Khan K.A., Akhter M.R., Singh N., et al. Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of cervical cancer. Microb Pathog. 2020;143:104131. DOI: 10.1016/j.micpath.2020.104131

9. Novikova T. Optical techniques for cervical neoplasia detection. Beilstein J Nanotechnol. 2017;8:1844–62. DOI: 10.3762/bjnano.8.186

10. Malati T. Tumour markers: An overview. Indian J Clin Biochem. 2007;22(2):17–31. DOI: 10.1007/BF02913308

11. Bahrami A., Hasanzadeh M., Shahidsales S., Farazestanian M., Hassanian S.M., Moetamani Ahmadi M., et al. Genetic susceptibility in cervical cancer: from bench to bedside. J Cell Physiol. 2018;233(3):1929–39. DOI: 10.1002/jcp.26019

12. Van Ostade X., Dom M., Tjalma W., Van Raemdonck G. Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer. Arch Gynecol Obstet. 2018;297(2):295–311. DOI: 10.1007/s00404-017-4587-2

13. Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217–36. DOI: 10.1002/cam4.1501

14. Walker J.L., Wang S.S., Schiffman M., Solomon D. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol. 2006;195(2):341–8. DOI: 10.1016/j.ajog.2006.02.047

15. Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97(14):1066–71. DOI: 10.1093/jnci/dji186

16. Campitelli M., Jeannot E., Peter M., Lappartient E., Saada S., de la Rochefordière A., et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One. 2012;7(8):e43393. DOI: 10.1371/journal.pone.0043393

17. Kontostathi G., Zoidakis J., Anagnou N.P., Pappa K.I., Vlahou A., Makridakis M. Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. Expert Rev Proteomics. 2016;13(8):731–45. DOI: 10.1080/14789450.2016.1210514

18. Matsuo K., Machida H., Mandelbaum R.S., Konishi I., Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2019;152:87–93. DOI: 10.1016/j.ygyno.2018.10.026

19. Choi K.H., Lee S.W., Yu M., Jeong S., Lee J.W., Lee J.H. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. J Gynecol Oncol. 2019;30(1):e1. DOI: 10.3802/jgo.2019.30.e1

20. Xu F., Li Y., Fan L., Ma J., Yu L., Yi H., et al. Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage. J Cancer. 2018;9:1660–66. DOI: 10.7150/jca.24049

21. Yang H., Hu H., Gou Y., Hu Y., Li H., Zhao H., et al. Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma. Int J Clin Oncol. 2018;23:321–8. DOI: 10.1007/s10147-017-1210-2

22. Xu D., Wang D., Wang S., Tian Y., Long Z., Ren X. Correlation between squamous cell carcinoma antigen level and the Clinicopathological features of early-stage cervical squamous cell carcinoma and the predictive value of squamous cell carcinoma antigen combined with computed tomography scan for lymph node metastasis. Int J Gynecol Cancer. 2017;27:1935–42. DOI: 10.1097/IGC.0000000000001112

23. Markovina S., Wang S., Henke L.E., Luke C.J., Pak S.C., DeWees T., et al. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. Br J Cancer. 2018;118:72–8. DOI: 10.1038/bjc.2017.390

24. Kubik S., Moszynska-Zielinska M., Fijuth J., Tomalczyk A., Jesionek- Kupnicka D., Ura L., et al. Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse. Prz Menopauzalny. 2019;18(1):23–6. DOI: 10.5114/pm.2019.84153

25. Huang E.Y., Huang Y.J., Chanchien C.C., Lin H., Wang C.J., Sun L.M., et al. Pretreatment carcinoembryonic antigen level is a risk factor for Para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiat Oncol. 2012;7:13. DOI: 10.1186/1748-717X-7-13

26. Mabuchi S., Isohashi F., Yokoi T., Takemura M., Yoshino K., Shiki Y., et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol. 2016;141:240–6. DOI: 10.1016/j.ygyno.2016.02.011

27. Wang W., Liu X., Meng Q., Zhang F., Hu K. Prophylactic extendedfield irradiation for patients with cervical Cancer treated with concurrent Chemoradiotherapy: a propensity-score matching analysis. Int J Gynecol Cancer. 2018;28:1584–91. DOI: 10.1097/IGC.0000000000001344

28. Takeda M., Sakuragi N., Okamoto K., Todo Y., Minobe S.I., Nomura E., et al. Preoperative serum SCC, CA125 and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand. 2002;81(5):451–7. DOI: 10.1034/j.1600-0412.2002.810513.x

29. Fu J., Wang W., Wang Y., Liu C., Wang P. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 2019;14(1):146. DOI: 10.1186/s13014-019-1355-4

30. Farzaneh F., Shahghassempour S., Noshine B., Arab M., Yaseri M., Rafizadeh M., et al. Application of tumor markers SCC-Ag, CEA, and TPA in patients with cervical precancerous lesions. Asian Pac J Cancer Prev. 2014;15(9):3911–4. DOI: 10.7314/apjcp.2014.15.9.3911

31. Kotowicz B., Fuksiewicz M., Jonska-Gmyrek J., Bidzinski M., Kowalska M. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumour Biol. 2016;37(1):1271–8. DOI: 10.1007/s13277-015-3914-0

32. Konishi T., Shimada Y., Hsu M., Tufts L., Jimenez-Rodriguez R., Cercek A., et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4(3):309–15. DOI: 10.1001/jamaoncol.2017.4420

33. Lin Y.H., Wu C.H., Fu H.C., Chen Y.J., Chen Y.Y., Ou Y.C., et al. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer. Cancer Biomark. 2020;28(3):285–92. DOI: 10.3233/CBM-201455

34. Molina R., Filella X., Lejarcegui J.A., Pahisa J., Torné A., Rovirosa A., et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 2003;24(3):156–64. DOI: 10.1159/000073846

35. Huang G., Chen R., Lu N., Chen Q., Lv W., Li B. Combined Evaluation of Preoperative Serum CEA and CA125 as an independent prognostic biomarker in patients with early-stage cervical adenocarcinoma. Onco Targets Ther. 2020;13:5155–64. DOI: 10.2147/OTT.S250614

36. Campbell J.D., Yau C., Bowlby R., Liu Y., Brennan K., Fan H., et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 2018;23(1):194–212.e6. DOI: 10.1016/j.celrep.2018.03.063

37. Gadducci A., Guerrieri M.E., Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol. 2013;86(2):104– 29. DOI: 10.1016/j.critrevonc.2012.09.003

38. Xie R., Yang Y., Zhang H., Liu H., Guo J., Qin H., et al. c-Myb and its Effector COX-2 as an indicator associated with prognosis and therapeutic outcome in colorectal cancer. J Cancer. 2019;10(7):1601–10. DOI: 10.7150/jca.27261

39. Karageorgopoulou S., Kostakis I.D., Gazouli M., Markaki S., Papadimitriou M., Bournakis E., et al. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum- based chemotherapy. Clinical Trial BMC Cancer. 2017;17(1):451. DOI: 10.1186/s12885-017-3435-x

40. Li W., Ma H., Zhang J., Zhu L., Wang C., Yang Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017;7(1):13856. DOI: 10.1038/s41598-017-14364-2

41. Fu Z., Zhang P., Luo H., Huang H., Wang F. CXCL12 modulates the radiosensitivity of cervical cancer by regulating CD44. Mol Med Rep. 2018;18(6):5101–8. DOI: 10.3892/mmr.2018.9554

42. Dasari S., Rajendra W., Valluru L. Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients. Med Oncol. 2014;31(9):139. DOI: 10.1007/s12032-014-0139-9

43. Sidorkiewicz I., Piskór B., Dąbrowska E., Guzińska-Ustymowicz K., Pryczynicz A., Zbucka-Krętowska M., et al. Plasma levels and tissue expression of selected cytokines, metalloproteinases and tissue inhibitors in patients with cervical cancer. Anticancer Res. 2019;39(11):6403–12. DOI: 10.21873/anticanres.13854

44. Li Y., Wu T., Zhang B., Yao Y., Yin G. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med Oncol. 2012;29(5):3394–9. DOI: 10.1007/s12032-012-0283-z

45. Roslind A., Palle C., Johansen J.S., Christensen I.J., Nielsen H.J., Mosgaard B.J. Prognostic utility of serum YKL-40 in patients with cervical cancer. Scand J Clin Lab Invest. 2020;80(8):687–93. DOI: 10.1080/00365513.2020.1846209

46. Anggraeni T.D., Rustamadji P., Aziz M.F. Fas Ligand (FasL) in Association with Tumor-Infiltrating Lymphocytes (TILs) in early stage cervical cancer. Asian Pac J Cancer Prev. 2020;21(3):831–5. DOI: 10.31557/APJCP.2020.21.3.831